Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized double-blind placebo-controlled study of 610 in adults with eosinophilic asthma
CTR20244205Phase 2Active
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 610 in asthma, eosinophilic asthma (EA), sponsored by 3S Guojian Pharmaceutical. Started Dec 2024; status: active.
02
Drugs
610
03
Conditions
asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on CTR20244205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244205.